ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3733-3739

  Kedrin, Dmitriy ^a   Wyckoff, Jeffrey ^a   Boimel, Pamela J ^a   Coniglio, Salvatore J ^a   Hynes, Nancy E ^b   Arteaga, Carlos L ^c   Segall, Jeffrey E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; AC 480; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ANIMALS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TYRPHOSTINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66649126942     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2163     Document Type: Article

References (24)

1. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004;5:525-531
2. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258. (Pubitemid 47559211)
3. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007;25:4405-4413 (Pubitemid 350013846)
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-252 (Pubitemid 28399649)
5. Xue C, Liang F, Mahmood R, et al. ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 2006;66:1418-1426 (Pubitemid 43259922)
6. Xue C, Wyckoff J, Liang F, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006;66:192-197 (Pubitemid 43166025)
7. Zhan L, Xiang B, Muthuswamy SK. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res 2006;66:5201-5208 (Pubitemid 43844943)
8. Minn AJ, Gupta GP, Padua D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 2007;104:6740-6745 (Pubitemid 47175571)
9. Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE. Intracellular expression of a single-chain antibody directed to the EGFR leadsto growth inhibition of tumor cells. Oncogene 1996;13:275-282 (Pubitemid 26334859)
10. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cellsan d macrophagesis required for tumor cell migration in mammary tumors. Cancer Res 2004;64:7022-7029 (Pubitemid 39331012)
11. Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Unit 19.7 imaging tumor cell movement in vivo. Curr Protocol Cell Biol 2007;19:7.
12. Wong TW, Lee FY, Yu C, et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-6193 (Pubitemid 44703785)
13. Sahai E, Wyckoff J, Philippar U, Segall JE, Gertler F, CondeelisJ. Simultaneous imaging of GFP, CFP and collagen in tumors in vivo using multiphoton microscopy. BMC Biotechnol 2005;5:14.
14. CondeelisJ, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003;3:921-930 (Pubitemid 37500177)
15. Wyckoff JB, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007;67:2649-2656 (Pubitemid 46548952)
16. Spector NL, Xia W, BurrisH III, et al. Study of the biologic effectsof lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-2512 (Pubitemid 47050840)
17. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000;60 Suppl 1:33-40, discussion 1-2.
18. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-over-expressing breast cancer cells in vitro and in vivo. Cancer Res2001;61:8887-8895
19. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-1788
20. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995;15:1182-1191
21. Mamoune A, Kassis J, Kharait S, et al. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res 2004;299:91-100. (Pubitemid 39078384)
22. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol- 3 kinase. J Biol Chem 1998;273:28238-28246 (Pubitemid 28496122)
23. Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL. ErbB2 isne cessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 2000;148:385-397 (Pubitemid 30078250)
24. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726 (Pubitemid 34111379)